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Basic Science
Relationship Between Vascular Endothelial Growth Factor and Nuclear 
Factor-κB in Renal Cell Tumors
Aim To assess the relationship between protein and messenger RNA 
(mRNA) levels of vascular endothelial growth factor (VEGF) and subcel-
lular localization of nuclear factor-kappa B (NF-κB), proliferation rate of 
tumor cells, and clinicopathological characteristics of renal cell tumors.
Methods We analyzed 31 one renal cell tumors – 22 clear cell renal cell 
carcinomas (CCRCC) and 9 other histologic types (non-CCRCC). 
VEGF expression and subcellular localization of p65 member of NF-κB 
and Ki67 were immunohistochemically evaluated for the proliferation 
rate of tumor cells. Expression of VEGF mRNA was assessed using quan-
titative real-time polymerase chain reaction after total RNA extraction 
from snap-frozen tumor tissue samples.
Results Cytoplasmic localization of VEGF protein in renal cell tumors 
showed a perimembranous and diffuse pattern, the former being more 
evident in CCRCC (27.1 ± 18.9 vs 3.3 ± 10 % tumors, P<0.001) and 
the latter in non-CCRCC type (71.7 ± 23.2 vs 31.1 ± 22.1 % tumors, 
P < 0.001). Heterogeneity in VEGF gene expression was more pro-
nounced in CCRCC type than in non-CCRCC type (P = 0.004). In ad-
dition, perimembranous VEGF pattern was associated with higher VEGF 
mRNA levels (P = 0.006) and diffuse VEGF pattern with lower VEGF 
mRNA levels (P < 0.001). Nuclear and cytoplasmic staining of NF-κB/
p65 was observed in the majority of tumor cells. A significant association 
was recorded between cytoplasmic NK-κB/65 staining and VEGF stain-
ing of diffuse pattern (P = 0.026). Association between NF-κB/65 and 
proliferation rate of tumor cells was significant for cytoplasmic staining 
(P = 0.039) but not for nuclear NFkB/p65 staining (P = 0.099).
Conclusion Higher but inhomogeneous expression of VEGF in tumor 
cells, especially in CCRCCs, is associated with NF-κB/65 activity. This 
indicates that both VEGF and NF-κB/65 may be important in renal car-
cinogenesis, representing a possible molecular target in the treatment of 
renal cell carcinoma.
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Renal cell carcinoma is a malignancy with a 
variable clinical course, which is partly attrib-
utable to different genetic structure of differ-
ent renal cell carcinoma types (1). The major-
ity of clear cell renal cell carcinoma (CCRCC) 
types are associated with the loss of heterozy-
gosity in several regions along the short arm of 
chromosome 3, including the regions where 
von Hippel-Lindau, FHIT, RASSF1A, and 
DRR1 genes are located. The loss of function 
of von Hippel-Lindau gene leads to aberrant 
activation of hypoxic response in terms of up-
regulation of angiogenic factors and conse-
quent neovascularization (2).
Angiogenesis is an important process for 
tumor progression and metastatic spread. One 
of the major factors that regulate this process 
is vascular endothelial growth factor (VEGF) 
(3). Angiogenic factors are newly synthesized 
by the mechanism of inducible transcriptional 
initiation of their genes. This phenomenon is 
governed by transcription factors, which bind 
to the regulatory regions of genes.
The nuclear factor-kappa B (NF-κB) is 
a transcription factor that plays an impor-
tant role in the control of growth, differenti-
ation, and apoptosis. It consists of homodi-
mers and heterodimers composed of several 
subunits as follows: NF-κB1 (p50/p105), NF-
κB2 (p52/100), Rel A (p65), Rel B, and c-Rel 
proteins (4). The inactive form of NF-κB is 
localized in the cytoplasm and consists of the 
DNA-binding p50 and p65 subunits and an 
inhibitory subunit called IκB, which is bound 
to p65. IκB masks the nuclear localization se-
quence, and its release initiates the activation 
of NF-κB and its subsequent translocation to 
the nucleus, where it can bind to DNA tar-
get sites (5). Activation of NF-κB may be trig-
gered by a variety of cytokines, growth factor 
receptors, and tyrosine kinase.
Activation of NF-κB results in the induc-
tion of a large number of genes involved in 
the regulation of a wide variety of biologi-
cal responses, including anti-apoptotic genes, 
cell cycle-regulatory genes, genes encoding ad-
hesion molecules, chemokines, inflammato-
ry cytokines, genes involved in metastases, cy-
clooxygenase, and VEGF (6-10). There is also 
increasing evidence that NF-κB is implicated 
in oncogenesis (11).
The aim of this study was to assess protein 
and messenger RNA (mRNA) levels of VEGF 
and to compare their values with subcellular 
localization of NF-κB, proliferation rate of tu-
mor cells, and clinicopathological characteris-
tics of renal cell tumors.
Patients and methods
Clinicopathological data
We collected unfixed material from 70 con-
secutive nephrectomy specimens from pa-
tients surgically treated for renal cell neoplasm 
in the period from 2003 to 2004 at the De-
partment of Urology, Rijeka University Hos-
pital Center, Rijeka, Croatia. The final sample 
comprised 31 renal cell tumor and 22 non-tu-
mor nephrectomy specimens with adequate 
mRNA for further real-time polymerase chain 
reaction (PCR). All samples were snap-frozen 
in liquid nitrogen, stored at -80°C, fixed in 4% 
buffered formalin, embedded in paraffin, and 
routinely stained with hematoxylin and eo-
sin. Data on sex, age, tumor size, tumor-node-
metastases stage, histologic subtype according 
to the World Health Organization classifica-
tion (12), and nuclear grade according to the 
Fuhrman nuclear grading system (13) were 
obtained from patient medical records and 
files of the Department of Pathology, Rijeka 
University School of Medicine.
Immunohistochemistry
Tumor samples were immunohistologically 
analyzed in a Dako Autostainer Plus (Dako-
Cytomation Colorado Inc, Fort Collins, CO, 
USA) according to the manufacturer’s pro-
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tocol, using Envision peroxidase procedure 
(ChemMate TM Envision HRP detection 
Kit K5007, DakoCytomation, Glostrup, Den-
mark). Epitope retrieval was achieved by im-
mersing slides in Tris-EDTA buffer (pH 9.0) 
and boiling water bath for 10 minutes. Slides 
were left to cool for 45 minutes and were pre-
incubated with blocking solution, containing 
normal goat serum (DakoCytomation), for 
30 minutes. VEGF expression was determined 
by mouse monoclonal antibody VEGF (C-
1: sc-7269, dilution 1:100, overnight incuba-
tion at 4şC; Santa Cruz Biotechnology, San-
ta Cruz, CA, USA). Subcellular localization of 
p65 member of NF-κB was determined with 
mouse monoclonal antibody NF-κB p65 (F-6: 
sc-8008; dilution 1:50, overnight incubation 
at 4°C; Santa Cruz Biotechnology). Prolifer-
ative activity was assessed by detecting Ki67 
protein with monoclonal antibody (clone 
MIB-1, dilution 1:50; DakoCytomation).
EnVisionTM G/2 Doublestain System 
(K5361, DakoCytomation) was used for de-
tection of Ki67 nuclear positivity with chro-
mogen DAB and VEGF cytoplasmic positivi-
ty with Fast Red. Negative control slides were 
prepared by substituting Dako ChemMate an-
tibody diluent for secondary antibody.
Evaluation of immunostaining
Immunohistochemical staining results were 
evaluated independently by two pathologists 
unaware of the clinicopathological data of 
the patients. No interobserver variability was 
found for the two observers.
The intensity of VEGF immunostain-
ing was semiquantitatively assessed as fol-
lows: 0 – none, 1 – weak, 2 – moderate, and 
3 – strong. The immunoreactive score was 
calculated by multiplying the intensity (I) 
with the percentage of positive tumor cells 
(VEGF Histo-score = [percentage of positive 
tumor cells × I1]+[percentage of positive tu-
mor cells × I2]+[percentage of positive tumor 
cells × I3]). Furthermore, VEGF cytoplasmic 
expression was evaluated as the percentage of 
diffuse and perimembranous staining pattern 
in tumor cells. Smooth muscle cells in vascu-
lar walls served as internal control. For statis-
tical analysis, we used only VEGF expression, 
determined as diffuse and perimembranous, 
since the analysis with VEGF H-score showed 
no significant results.
Nuclear and cytoplasmic NF-κB/p65 in-
tensity of immunoreactivity was graded as fol-
lows: 0 – none, 1 – weak, 2 – moderate, and 
3 – strong. The percentage of neoplastic cells 
with cytoplasmic staining was approximately 
determined in the entire tumor area, while the 
percentage of nuclear staining was determined 
by counting positive tumor nuclei in 500 tu-
mor cells in the tumor areas with the high-
est density of positive cells, using ×60 power 
field and squared graticule (U-OCMSQ7/7, 
Olympus, Zagreb, Croatia). The immunoreac-
tive score for cytoplasmic and nuclear staining 
of NF-κB/p65 (Histo-score) was calculated 
in the same way as the score for VEGF. Cyto-
plasmic staining of tumor and non-tumor cells 
served as internal positive control.
Ki67 index (percentage of positive cells) 
was determined by counting 500 tumor cells 
under ×400 magnification in the tumor ar-
eas with the highest proliferative activity. The 
counting was performed by ISSA 3.1 software 
(Vams, Zagreb, Croatia). A sample was con-
sidered positive if any nuclear staining was 
seen.
RNA isolation, reverse transcription PCR, and 
real-time PCR
Fresh tissue was homogenized using MagNA 
Lyser (Roche Applied Science, Rotkreuz, Swit-
zerland) according to the protocol consisting 
of 2 folds for 50 seconds at 6500 rpm separat-
ed by 90 seconds of cooling. Total RNA was 
extracted from the frozen tissues using Nu-
cleospin RNA II isolation kit (Macherey-Na-
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gel, Düren, Germany), according to the manu-
facturer’s instructions.
One microgram of total RNA was reverse-
transcribed to a single strand cDNA in a final 
volume of 20 μL in two steps according to the 
manufacturer’s instructions. In the first step, 
pre-mix with RNA, random primers, dNTPs, 
and water were denatured at 70şC for 5 min-
utes. In the second step, SuperScriptTM III Re-
verse Transcriptase (Cat. No. 18080-093, Invi-
trogen, Milan, Italy), buffer, DTT, and RNase 
inhibitor were added and left for 5 minutes at 
room temperature, followed by heating for 60 
minutes at 55şC, 15 minutes at 70şC, and 5 
minutes at 95şC. All reagents were obtained 
from Invitrogen. Negative control for reverse 
transcription was water instead of RNA.
Relative VEGF mRNA quantification was 
performed using a fluorescence-based real-
time detection method at ABI Prism 7300 
Sequence Detection System (Applied Biosys-
tems, Foster City, CA, USA). Oligonucleotide 
primers and probe for VEGF were purchased 
from Applied Biosystems as Inventoried Gene 
Expression Assay (Assay ID Hs00900054_
m1) consisting of 20 × mix of unlabeled PCR 
primers and TaqMan FAM probe. Oligo-
nucleotide primers and the probe for the en-
dogenous control β-actin gene were pur-
chased from Applied Biosystems as TaqMan 
FAM/TAMRA probe as follows: β-actin F 5′ 
CGAGCGCGGCTACAGCTT 3′, β-actin 
R 5′ TCCTTAATGTCACGCACGATTT 
3′, and β-actin probe 6Fam-ACCACCACG-
GCCGAGCGG-Tamra.
A 12-μL reaction mixture containing 2.5 
μL of cDNA template, 6.25 μL TaqMan Uni-
versal PCR master mix (Cat. No. 4326708, 
Applied Biosystems), and 0.62 μL primer 
probe mixture was amplified using the follow-
ing thermal cycler parameters: incubation at 
50°C for 2 minutes and denaturation at 95°C 
for 10 minutes, followed by 40 cycles of the 
amplification step (denaturation at 95°C for 
15 seconds and annealing/extension at 60°C 
for 1 minute). All amplification reactions were 
performed in triplicate. As negative control, 
samples with PCR mix and reverse transcrip-
tion PCR negative control were used. To ob-
tain the mRNA quantification of VEGF gene, 
results were calculated using ΔΔCT method 
and SDS software 1.3.1. (Applied Biosystems). 
The mRNA of the MDA231 mammary carci-
noma cell line was used as a calibrator and the 
β-actin gene was used as endogenous control. 
To normalize the data, ΔΔCT was calculat-
ed using the mean ΔCT values of each sample 
from which the mean ΔCT value of calibra-
tor was subtracted; relative quantitation value 
was expressed as 2- ΔΔCT. For two-way statisti-
cal analysis, VEGF gene expression was deter-
mined as low or high using the median as the 
cut-off value.
Statistical analysis
Statistical analysis was performed using Sta-
tistica 6.1 software (StatSoft, Inc., Tulsa, OK, 
USA). The distribution of data was tested for 
normality using Kolmogorov-Smirnov test. 
Pearson χ2 test was used to assess the signifi-
Table 1. Patohistological, immunohistochemical, and molecular 
characteristics of renal cell tumors
Characteristics CCRCC* non-CCRCC† P
Tumor size (cm, mean±SD)   7.8 ± 3.6   6.3 ± 3.5  0.299‡
Pathological stage (No.):
  1  13   6  0.443§
  2   9   3
Nuclear grade (No.):  
  1  15   5  0.505§
  2   7   4
VEGF (%, mean±SD):
  perimembranous  27.1 ± 18.9   3.3 ± 1.0  0.001‡
  diffuse  31.1 ± 22.1  71.7 ± 23.2 <0.001‡
Ki67 index (%, mean±SD)  13.4 ± 9.2   7.9 ± 5.6  0.106‡
NF-κB/p65 (histo-score, 
 mean±SD):
  nuclear 103.2 ± 64.9  98.4 ± 63.9  0.852‡
  cytoplasmic 214.5 ± 58.5 225.6 ± 58.1  0.637‡
VEGF mRNA (RQ) 
 (median, range)║  10.2 (0.3-142.2)   2.3 (0.05-14.9)  0.004
¶
Number of cases  22   9
*Abbreviations: CCRCC – clear cell renal cell carcinoma; VEGF – vascular endothelial 
growth factor; NF-κB – nuclear factor-κB; SD – standard deviation.




║Relative quantity of VEGF mRNA calculated using ΔΔCT method.
¶Mann-Whitney U-test.
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cance of association between categorical data 
such as tumor histologic type, nuclear grade, 
and pathologic stage. The measures of central 
tendency for continuous data such as tumor 
size, Ki67 index, VEGF mRNA levels, and 
VEGF and NF-κB/65 immunohistochemi-
cal staining were compared by t test or Mann-
Whitney U test, depending on data dis-
tribution. Pearson correlation was used to 
determine the association between VEGF 
immunohistochemical and gene expression, 
as well as between NF-κB/65 and VEGF im-
munohistochemical staining and Ki67 index. 
The level of statistical significance was set at 
P < 0.05.
Results
Immunoreactivity of VEGF, NF-κB/65, and Ki67 in 
renal cell tumors
Clinicopathological characteristics of renal 
cell tumors are presented in Table 1. VEGF 
immunohistochemical expression in renal cell 
tumors showed a perimembranous staining 
pattern (mean number of tumors, 20.2 ± 19.9) 
or diffuse pattern (mean, 42.9 ± 28.9). In gen-
eral, VEGF expression was more heteroge-
neous in CCRCCs with strong immunoreac-
tivity and more often observed at tumor edges, 
around necrosis and hemorrhagic zone. In 
non-CCRCCs, VEGF expression was more 
Figure 1. Immunohistochemical expression of vascular endothelial growth factor (VEGF), Ki67, and nuclear factor kappa B (NF-κB) in renal cell 
carcinoma. Double immunostaining for VEGF and Ki67 shows (A) the area with cytoplasmic VEGF positive (red staining) and Ki67 nuclear negative 
tumor cells and (B) focus with many Ki67 positive (brown staining) and VEGF negative tumor cells. (C) NF-κB/p65 immunostaining in the renal cell 
carcinoma with nuclear and/or cytoplasmic staining, which is less (C) or more (D) extensively expressed. Magnification ×400.
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homogeneous, mostly showing a diffuse pat-
tern. The difference in VEGF expression be-
tween CCRCC and non-CCRCC types was 
significant (P < 0.001).
Nuclear positivity for Ki67 was variably 
distributed within the tumors. Double im-
munostaining did not show an association be-
tween Ki67 and VEGF positivity (Figure 1). 
Besides, there was no difference in the mean 
value of Ki67 proliferation index (Table 1) be-
tween CCRCCs and non-CCRCCs.
NF-κB/p65 was detected in the cytoplasm 
of normal and tumor cells. Nuclear positivity 
was observed in tumor cells (Figure 1); howev-
er, a very weak and rare nuclear positivity was 
also detected in renal tubular cells. Nuclear 
staining in tumor cells was considered to be a 
mark of NF-κB activation. The majority of re-
nal cell tumors showed a high activation rate 
of NF-κB/p65, with heterogeneous distribu-
tion of staining intensity (mean H-score val-
ue 101.8 ± 63.6). Cytoplasmic NF-κB/p65 
staining of different intensity was detected in 
almost all renal cell carcinoma cells (mean H-
score value 217.7 ± 57.6). There was no sig-
nificant difference between the two groups of 
renal cell tumors according to nuclear or cyto-
plasmic staining of NF-κB/p65 (Table 1).
Association between gene and protein VEGF 
expression in renal cell tumors
VEGF mRNA levels differed between 
CCRCCs and non-CCRCCs (Table 1). 
VEGF gene expression was significantly higher 
in CCRCCs (median, 10.2; range, 0.3-142.2) 
than in non-CCRCCs (median, 2.3; range, 
0.05-14.9) (P = 0.004). There was no signifi-
cant difference in VEGF gene expression ei-
ther between all renal cell tumors (median, 
7.7; range, 0.05-142.2) and normal renal tissue 
(median, 4.9; range, 0.4-9.4) or between non-
CCRCCs and normal renal tissue (Figure 2). 
On the other hand, VEGF mRNA levels were 
significantly higher in CCRCCs than in nor-
mal renal tissue (P = 0.013). There was an as-
sociation between VEGF protein and VEGF 
mRNA levels in renal cell tumors. VEGF gene 
was up-regulated in tumors showing perimem-
branous staining pattern and down-regulated 
in tumors displaying diffuse staining pattern 
(Table 2).
Association between NF-κB/p65, Ki67, VEGF, and 
clinicopathological parameters
The relationship between subcellular localiza-
tion of NF-κB/p65, VEGF expression, prolif-
eration rate of tumor cells, and clinicopatho-
logical characteristics of CCRCC is shown 
in Table 3. Nuclear staining of NF-κB/p65 
did not show a significant association with 
VEGF gene expression. Cytoplasmic NF-κB/
p65 positivity was found within tumor cells 
mostly showing diffuse VEGF staining pat-
tern (P = 0.026) and a higher proliferation 
Table 3. Association of nuclear factor kappa-B (NK-κB)/p65 with pathological parameters and vascular endothelial growth factor 
(VEGF) in clear cell renal cell carcinoma (n = 22)
Pathological stage* VEGF mRNA (RQ)*‡ Immunohistochemical VEGF expression†
1, 2 3, 4 Ki67 index† low high perimembranous diffuse
NK-κB/p65 120.3 (29-247.1)  75.2 (23.3-190.2) 0.360  64.8 (23.3-152.3) 94.2 (27-247.1) -0.126 0.111
P 0.029 0.099 0.082    0.578 0.624
Cytoplasmic NK-κB/p65 250 (100-300) 200 (120-250) 0.443 200 (150-300) 200 (100-300) -0.215 0.472
P 0.018 0.039 0.393   0.336 0.026
*Mann-Whitney U-test, median (range).
†r, Pearson correlation.
‡Relative quantity of VEGF mitochondrial RNA (mRNA) calculated using ΔΔCT method, median cut-off value for low and high is 10.2 (0.3-142.2).
Table 2. Association of immunohistochemical and gene expres-
sion of vascular endothelial growth factor (VEGF) in renal tu-
mors (n = 31)
Immunohistochemical VEGF mRNA (RQ)*
VEGF expression (%) low high P†
Perimembranous (median, range)  0 (0-70) 30 (0-50)  0.006
Diffuse (median, range) 60 (15-100) 20 (0-60) <0.001
*Relative quantity (RQ) of VEGF mitochondrial RNA (mRNA) calculated using ΔΔCT 
method, median cut-off value for low and high VEGF is 7.7 (0.05-142.2).
†Mann-Whitney U test.
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rate (P = 0.039) in patients with localized dis-
ease (P = 0.018).
Discussion
We found that immunohistochemical expres-
sion of VEGF protein is associated with rela-
tive quantity of VEGF mRNA in renal cell 
carcinoma. We also found a relationship be-
tween the expression of activated NF-κB and 
angiogenic factor in renal cell carcinoma. 
Since renal cell carcinoma do not respond to 
conventional radio- and chemotherapy, one 
of the many challenges in the effective man-
agement of this type of tumor is identification 
of new molecular markers capable of predict-
ing tumor aggressiveness, disease progression, 
and therapeutic target (14). The recent devel-
opments in the understanding of the underly-
ing biology of renal cell carcinoma have identi-
fied VEGF as a logical therapeutic target (15). 
On the other hand, many studies of the NF-
κB pathway identified NF-κB as a therapeutic 
target (16,17). Our study suggests that both 
VEGF and NF-κB/65 should be considered as 
possible molecular targets in the treatment of 
patients with renal cell carcinoma.
We first tried to explore whether the ex-
pression of VEGF protein in tumor cells was 
associated with an increase in VEGF mRNA 
expression. Since there are different immuno-
histochemical phenotypes among tumor cells, 
it is difficult to recognize biologically different 
clones of tumor cells, which may be of great 
practical importance. Several studies inves-
tigated VEGF mRNA expression and/or ex-
pression of VEGF protein in renal cell carci-
noma (14). Our results are in part consistent 
with previous findings, demonstrating VEGF 
protein in nearly 30% of CCRCCs (18,19). 
Besides, our study offered more information 
on VEGF staining pattern and differences be-
tween CCRCCs and non-CCRCCs. There 
was a higher heterogeneity in protein and mo-
Figure 2. Comparison of vascular endothelial growth factor (VEGF) 
messenenger RNA (mRNA) relative quantity (A) between normal renal 
tissue and all renal cell tumors (P = 0.089, Mann-Whitney U-test), (B) be-
tween normal renal cell tissue and clear cell renal cell carcinoma (CCRC) 
(P = 0.013, Mann-Whitney U-test), and (C) between normal renal tissue 
and non-CCRCC (P = 0.676, Mann-Whitney U-test). Box represents me-
dian value and whisker plot represents range.
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lecular VEGF expression in CCRCCs than in 
non-CCRCCs, which is in accordance with 
previous findings that CCRCCs and non-
CCRCCs behave differently (20-22).
We have already reported on the associa-
tion we found between diffuse cytoplasmic 
staining and lower degree of vascularization 
and between perimembranous staining and 
higher degree of vascularization (22). The pres-
ent study showed the up-regulation of mRNA 
VEGF only in renal cell tumors with perimem-
branous VEGF expression. This finding points 
to the importance of recognizing different pat-
terns of VEGF expression, which could proba-
bly be associated with different angiogenic po-
tential of tumor cells in neovascularization.
We also found the subcellular localiza-
tion of NF-κB/p65 in renal cell carcinoma in 
the present study. Immunolocalization of p65 
was evident in the nucleus and the cytoplasm 
of renal cell tumors, while normal cells dis-
played predominantly cytoplasmic immunolo-
calization, with rare and very weak nuclear im-
munoreactivity. This observation suggests that 
p65 nuclear translocation may be an impor-
tant event during malignant transformation, 
as previously suggested (23).
NF-κB positivity has been reported in 
many malignancies, such as prostate cancer 
(24), laryngeal squamous cell carcinoma (25), 
pancreatic cancer (26), and breast cancer (27). 
NF-κB was localized both in the cytoplasm 
and in the nuclei of many malignant tumors 
(28,29), although in some of these, only cyto-
plasmic staining was observed (colorectal car-
cinoma) (30). In addition, the percentage of 
nuclear NF-κB also varied from only 5.6% of 
cells in oral squamous carcinoma (31,32) to 
more than 30% in prostate carcinoma (24), 
which is similar to ours and other studies (33).
Because nuclear localization of NF-κB is 
believed to be equivalent to NF-κB activa-
tion, we hypothesized that NF-κB was acti-
vated in some renal tumor cells, which may 
have triggered the transcription of NF-κB de-
pendent genes and regulated the expression 
of corresponding proteins. We further inves-
tigated whether the expression of VEGF was 
associated with subcellular localization of 
NF-κB/p65 and found that the constitutive 
activity of NF-κB/p65 was linked with higher 
expression of VEGF mRNA. This confirmed 
that NF-κB/p65 is involved in the VEGF ex-
pression (10). The cytoplasmic NF-κB was as-
sociated with diffuse VEGF expression. It is 
difficult to determine whether immunohis-
tochemical detection of a certain protein re-
flects its dynamic localization. The functional 
significance of this protein in the cytoplasm 
should be further explored. Nonetheless, the 
hypothesis of Nakayama et al (31) that the 
presence of a large amount of NF-κB in the 
cytoplasm may easily result in the activation 
of NF-κB, even by faint stimulation, seems 
quite reasonable.
Our study further demonstrated the asso-
ciation between cytoplasmic NF-κB/p65 and 
Ki67. It is known that NF-κB is an impor-
tant regulator of cell proliferation through its 
direct role in the cell cycle progression (34). 
It has been shown that NF-κB can stimu-
late transcription of cyclin D, a key regulator 
of G1 checkpoint control, mediated by direct 
binding of NF-κB to multiple sites in the cy-
clin D1 promoter (35,36). The potential mito-
gen activity of VEGF in renal cell tumors was 
not confirmed. Even more so, on double im-
munostaining with VEGF and Ki67 we could 
not confirm the co-localization of these two 
markers in the same cells. This finding does 
not absolutely exclude the possible influence 
of VEGF in tumor cell proliferation, but sug-
gests that proliferative activity in renal cell tu-
mors is controlled by some other mitogen fac-
tors in addition to VEGF.
Finally, cytoplasmic NF-κB/p65 associat-
ed with diffuse VEGF expression, found in the 
present study, together with previous results 
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(22) of higher Ki67 proliferative index, higher 
nuclear grade, and lower microvascular densi-
ty, separate this histologically worst-differenti-
ated renal cell carcinoma. Tumors with those 
histological and immunohistochemical char-
acteristics might behave more aggressively, al-
though in our study the pathologic stage was 
not worse in this group, likely because of the 
relatively small number of cases. On the oth-
er hand, renal cell tumors with perimembra-
nous VEGF expression and better differentia-
tion retain the angiogenic characteristics and 
the tumor contains more vasculature, similar 
to normal renal tissue (20,21).
In conclusion, the level of nuclear NF-κB/
p65 was higher in CCRCCs than in normal 
renal tissue and was related to higher VEGF 
expression, whereas cytoplasmic NF-κB/65 
was associated with a higher proliferation rate. 
These findings suggest that, among many dif-
ferent mechanisms of renal cell carcinoma 
progression, NF-κB may be a factor that con-
tributes to the aggressiveness of CCRCCs via 
increased angiogenic secretion and prolifera-
tion of tumor cells. NF-κB, in association with 
VEGF, may be an important target for the de-
velopment of future anti-tumor therapy for re-
nal cell carcinoma.
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